With healthcare expenditure in Asia projected to grow by 135 per cent to $2.3 trillion by 2026, the life sciences sector in the region continues to expand rapidly. At its new base at the Biopolis Biomedical Research Hub, Abcam joins over 350 life sciences companies, including eight of the top 10 global pharma players, that have laid down roots in the country. Abcam's new site will service the growing Asia Pacific (APAC) life sciences community, offering scientific and technical support, providing a commercial headquarters for the region. In conversation with BioSpectrum Asia, Rich Lane, Director- Sales and Marketing, APAC region, Abcam talks more about the company's growth plans in the APAC region. Edited excerpts;
What are the major plans in store for the new APAC hub at Singapore?
For a company like Abcam which strongly believes that collaboration is a big driver of progress, it is an exciting opportunity to join one of the world's leading life sciences clusters. We have long standing relationships with key local players (such as A*STAR, Singapore's Agency for Science, Technology and Research) and we are looking to build stronger connections with organisations that share our goal of pushing the boundaries of research.
We recognise that there is a growing mass of world-class academic institutes, biopharma, medtech and other organisations in APAC that need access to the latest innovations and support in order to progress and advance their research. We have established this physical presence at the centre, to be able to better understand their needs and enable us to work together more closely. Singapore is one of the most recognised locations for life sciences in APAC, so it is a great place to base ourselves.
How is the Singapore hub different from the other Abcam's centres in China and Australia?
Bu hikaye BioSpectrum Asia dergisinin June 2022 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BioSpectrum Asia dergisinin June 2022 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.
